

// ()
 //

" "

" p 16"

*

:

p16 (RAR)
 ()

() () ()

case-control :

stage

p16 RARB *grade PSA*

p16 RAR *MSPCR*

Odd's ratio

RAR :

RAR / *RAR* /

() () *RAR. (P< /)*
(P< /)

p16

() *p16 .* *p16* /
(P< /) ()

(P< /)

p16 RARB :

MSPCR p16 RARB :

mohammadhassanemranpour @ gmail.com :

() p16 (RARB) ()

() ()

()

()

()

()

stage grade PSA

()

RARB

p16

grade PSA

stage

case-control

()

grade PSA

stage

PSA

() stage grade

stage grade PSA

cc PSA

DNA

/

grading

DNA PCR DNA

housekeeping stage

PCR DNA

) PCR grade PSA

Housekeeping stage

PCR (

MSP housekeeping

p16

RARB

p16

DNA

RARB

Fisher Chi square

DNA

(MSP) PCR

() RARB p16

()

() PCR MSP

DNA

()

(/)

RAR / ± / / ± /

(P< /) / ± /

/ ± / PSA .

RAR Grade . / ±

RAR stage2 Stage

/ /

RAR

(P< /)

(OR=) RAR (/)

RAR (P< /)

OR= / /) / /

.(CI= % RAR

RAR			
(%)	(%)	(%)	RAR
(/)	(/)	()	
(/)	(/)	()	

(P< /) p16

p16 p16

p16 (/)

p16()

.(P< /) p16

p16			
()	()	(%)	P16
(/)	()	()	
(/)	()	()	

RAR

p16

p16

/

p16

(OR= /)

OR= / /)

/ /

.(CI= %

p16 RARB

CPG

grade PSA

RARB

stage

p16

ultra-structure

MSPCR

grade< Stage< PSA<

p16 RARB

(grade< stage< PSA <)

/ RAR

p16

grade> PSA>)

/ RAR

(stage>

/ p16

()

REFERENCES

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55(1): 10-30.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. *CA Cancer J Clin* 2004; 54(1): 8-29.
3. Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the management of prostate cancer. *Endocr Relat Cancer* 2006; 13(2): 357-77.
4. Blute ML. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. *J Urol* 2001; 165: 119-25.
5. Roberts WW. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. *Urology* 2001; 57: 1033-37.
6. Partin AW. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. *J Am Med Assoc* 1997; 277: 1445-51.
7. DeVita VT, Lawrence TS, Rosenberg SA. *Cancer: Principles & Practice of Oncology*. 7th ed. USA: Lippincott Williams & Wilkins. 2004; PP: 1206-70.
8. Maruyama R. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. *Clin Cancer Res* 2002; 8: 514-9.
9. Singal R. Polymorphisms in the methylene tetrahydrofolate reductase gene and prostate cancer risk. *Int J Oncol* 2004; 25: 1465-71.
10. Enokida HMI. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. *Int J Cancer* 2005; 116: 174-81.
11. Woodson K. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. *Prostate* 2003; 55: 199-205.
12. Bastian PJ. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. *Clin Cancer Res* 2005; 11: 4097-106.
13. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. *Clin Cancer Res* 2005; 11: 4037-43.